site stats

Cynapsedx

WebCynapseDx Limited Liverpool Science Park 131 Mount Pleasant Liverpool L3 5TF; 0151 705 3400; [email protected] WebCynapseDx is the new name for CellCap Technologies. The new name better reflects our focus on development of blood tests for Parkinson's and Alzheimer's diseases. It builds on the… Chief...

About Us CynapseDx

WebCynapseDx - Technology Neurodegenerative Disease Parkinson’s Disease and Alzheimer’s Disease have very different symptoms, but at a molecular level they may well have much … http://forum.cynapsedx.com/ first western film https://amdkprestige.com

News - Neurodegenerative Disease CynapseDx

Webcynapsedx.com Claim your profile to get in front of buyers, investors, and analysts. Submit Your Analyst Briefing Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Learn more. Overview & Products Financials People Alternatives & Competitors Customers CynapseDx has not claimed their Profile. http://cynapsedx.com/novel-aggregated-biomarker WebCynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as … camping donges 44480

CynapseDx - Crunchbase Company Profile & Funding

Category:CynapseDx - Contacts, Employees, Board Members, Advisors

Tags:Cynapsedx

Cynapsedx

Technology - Neurodegenerative Disease CynapseDx

WebCynapseDx Connect to CRM Summary Financials People Technology Signals & News Similar Companies Highlights Employee Profiles 2 About CynapseDx has 2 current employee profiles, including Co-Founder & CTO Christopher Stanley. Contacts We're working on getting contact data for CynapseDx Find more contact data in Search! Get … http://cynapsedx.com/news

Cynapsedx

Did you know?

WebJun 8, 2024 · CynapseDx develops products to isolate proteins or cells from whole blood. Its primary focus is neurodegenerative diseases, such as Parkinson’s or Alzheimer’s Disease.

WebJul 1, 2024 · March 26th 2024. PharmaKure is delighted to announce the completion of the acquisition of the CynapseDx assays for oligomeric proteins. This is the final step that secured invesment of £4 million from a private investor and the UK Future Fund to finance clinical trials on their leading drug candidate PK051 for Alzheimer's disease. 26 March 2024 Webwww.cynapsedx.com/about-us Formerly Known As Cell Cap Technologies Ownership Status Acquired/Merged (Operating Subsidiary) Financing Status Formerly VC-backed …

WebCynapseDx Company Name CynapseDx Main Industry Business Services, Research & Development Website www.cynapsedx.com Contact Information Headquarters 131 Mount Pleasant, Liverpool, England, L3 5TF, United Kingdom … WebSummary Overview Number of Founded Organizations 1 CB Rank (Person) 672,540 Gender Male Christopher Stanley is the co-founder of CynapseDx. Jobs Number of Current Jobs 1 Christopher Stanley is the Co-Founder & CTO at CynapseDx. CynapseDx Co-Founder & CTO Recent News and Activity There is no recent news or activity for this profile.

WebCynapseDx develops products to isolate proteins or cells from whole blood. Its primary focus is neurodegenerative diseases, such as Parkinson’s or Alzheimer’s Disease.

http://forum.cynapsedx.com/ first western insurance booneville arhttp://cynapsedx.com/about-us first western capital managementWebCynapseDx's key executives include Damian Bond and 2 others. Damian Bond Chief Executive Peter Foster Chairman Christopher Stanley Chief Technology Officer Source: cynapsedx.com Report incorrect company information Key Executive Tracking Receive notifications of key executive changes Get started Executives of similar companies Vivid … first western financeWebCynapseDx (formerly CellCap Technologies) is a company that develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from neurodegenerative diseases. It develops assays that can measure the oligomeric and aggregated forms of ß-amyloid, α-synuclein, and phospho-tau in blood. … camping domaine montcalm les mathesWebCynapseDx has been developing products to isolate proteins or cells from whole blood since 2012. At the heart of our techniques is an antibody coated large ultra-dense … camping door decoration ideasWebCynapseDx has been developing products to isolate proteins or cells from whole blood since 2012. At the heart of our techniques is an antibody coated large ultra-dense magnetic particle that can force its way through the viscous, cell-rich media of blood to encou nter and bind proteins. These can be free in plasma, or cell-associated. camping dreilandereck riedWebGemelli Biotech's main competitors include Vivid Genomics, ALCEDIAG, Quadrant Biosciences and CynapseDx. Compare Gemelli Biotech to its competitors by revenue, employee growth and other metrics at Craft. Advanced Product Craft Intelligence Portal Craft API Supplier Intelligence Platform Company Search (Free) Solutions Craft for … camping douce provence forcalquier